Results 221 to 230 of about 364,170 (283)

Universal Prophylactic Antitumor Vaccination Using Stem Cell Membrane‐Coated Nanoparticles

Advanced Materials, Volume 37, Issue 14, April 9, 2025.
Induced pluripotent stem cell membrane is coated onto adjuvant‐loaded nanoparticle cores to create a universal cancer vaccine. The formulation utilizes oncofetal antigens present on the cell membrane to elicit broadly protective immune responses in vivo.
Nishta Krishnan, Jiarong Zhou, Animesh Mohapatra, Christian John Ventura, Yaou Duan, Junyong Lee, Jacob J. Hoenig, Oliver Nizet, Weiwei Gao, Ronnie H. Fang, Liangfang Zhang   +10 more
wiley   +1 more source

Determinants of timely administration of the birth dose of hepatitis B vaccine in Senegal in 2019: Secondary analysis of the demographic and health survey. [PDF]

PLOS Glob Public Health
Bassoum O, Ba MF, Sougou NM, Sow A, Seck I.   +4 more
europepmc   +1 more source

Targeting hepatitis B vaccine escape using immunogenetics in Bangladeshi infants

, 2023
Butler-Laporte G, Auckland K, Noor Z, Kabir M, Alam M, Carstensen T, Wojcik GL, Chong AY, Pomilla C, Noble JA, McDevitt SL, Smits G, Wareing S, van der Klis FR, Jeffery K, Kirkpatrick BD, Sirima S, Madhi S, Elliott A, Richards JB, Hill AV, Duggal P, PROVIDE authors, Cryptosporidiosis Birth Cohort authors, Sandhu MS, Haque R, Petri WA, Mentzer AJ.   +27 more
europepmc   +1 more source

A 12-year cohort study on the efficacy of plasma-derived hepatitis B vaccine in rural newborns

, 2000
Hongbin Liu
openalex   +1 more source

Achieving Optimal Health With Host‐Directed Therapies (HDTs) in Infectious Diseases—A New Horizon

Advanced Therapeutics, Volume 8, Issue 4, April 2025.
Host‐directed therapies (HDTs) represent a transformative approach in infectious disease management by targeting host factors to enhance immune responses and inhibit viral replication. This innovative strategy leverages advanced genomics and gene editing technologies, offering promising avenues for improved patient outcomes and a new horizon in ...
Amol D. Gholap, Pankaj R. Khuspe, Sagar R. Pardeshi, Md Jasim Uddin, Ushasi Das, Navnath T. Hatvate, Satish Rojekar, Prabhanjan Giram, Mohammad Khalid, Yahya E. Choonara, Md. Faiyazuddin   +10 more
wiley   +1 more source

C-Phycocyanin and Phycocyanobilin as a Novel Adjuvant in Hepatitis B Vaccine. [PDF]

Iran J Pharm Res
Abdali N, Tabaripour R, Javadi S, Nasirikenari M, Birjandi M, Siavashi V, Naghavi MR, Hasani Z, Ahmari A, Hanifi H.   +9 more
europepmc   +1 more source

CpG‐Based Nanovaccines Enhance Ovarian Cancer Immune Response by Gbp2‐Mediated Remodeling of Tumor‐Associated Macrophages

Advanced Science, Volume 12, Issue 15, April 17, 2025.
CpG‐based nanovaccines bolster ovarian cancer immunotherapy via the Gbp2‐Pin1‐NFkB pathway‐mediated reprogramming of tumor‐associated macrophages (TAMs.) Moreover, this nanovaccine can alleviate chemotherapy‐induced immunosuppression by augmenting the proportion of M1‐like TAMs, enhancing the infiltration of CD8+ T cells, and downregulating the ...
Jiaqiang Xiong, Juyuan Huang, Hanxiao Xu, Qiuji Wu, Jiahui Zhao, Yurou Chen, Guanlan Fan, Haotong Guan, Rourou Xiao, Zhaojin He, Siqi Wu, Wenliang Ouyang, Shixuan Wang, Lu Zhang, Peng Xia, Wei Zhang, Meng Wu   +16 more
wiley   +1 more source

Animal models of human herpesvirus infection

Animal Models and Experimental Medicine, Volume 8, Issue 4, Page 615-628, April 2025.
Human herpesvirus can infect humans and other vertebrates, primarily targeting the skin, mucous membranes, and neural tissues, thereby significantly impacting the health of both humans and animals. Animal models are crucial for studying virus pathogenesis, vaccine development, and drug testing.
Ziqing Jia, Dong Zhang, Lin Zhu, Jing Xue   +3 more
wiley   +1 more source

Intralesional acyclovir versus intralesional Hepatitis-B vaccine in treatment of resistant plantar warts: a randomized controlled trial. [PDF]

Arch Dermatol Res
Gharib K, Taha A, Elradi M.
europepmc   +1 more source

Reactivity pattern of a human monoclonal antibody against recombinant hepatitis B vaccine to hbsag immune escape mutants

, 2000
Michel P. Cooreman, C. M. G. Sünnen, Lieven Verhoye, Mark H. Van Roosmalen, Wilma P. Paulij, Geert Leroux‐Roels   +5 more
openalex   +1 more source